Compare Moderna, Inc. (MRNA) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Rigetti Computing Inc — how do they compare? Moderna, Inc. trades at $224.92 (market cap $78.65B), while Rigetti Computing Inc trades at $14.03 (market cap $4.72B). The key difference: Moderna, Inc. is far larger — about 16.7× Rigetti Computing Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Rigetti Computing Inc for 35 Days on average.
| MRNA | RGTI | |
|---|---|---|
Market Cap | $78.65B | $4.72B |
Volume | 37,373,437 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $203.46 | $56.34 |
52-Week Low | $22.36 | $12.90 |
Typical Hold Time | 59 Days | 35 Days |
Enterprise Value | $74.80B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
RGTI trades at $14.03, down 3.84% with bearish technical signals despite bullish oscillators. The company shows minimal revenue of $7.09M (2025) with significant losses (-$216.21M net income) and negative margins. Analyst consensus remains strong with 85.71% buy ratings and $21.67 price target, while recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC partnerships.
RGTI presents high-risk speculative potential with Wall Street optimism contrasting weak fundamentals. The stock offers substantial upside to analyst targets but faces execution risks in commercializing quantum technology amid persistent cash burn and competitive pressures from better-funded peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
